Study terminated for strategic business reasons

The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.

Inclusion Criteria:

• Have type 2 diabetes
• Have a BMI of ≥27 kilograms per square meter (kg/m2)
• Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss)

Exclusion Criteria:

• Have a prior or planned surgical treatment for obesity,

• Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar state or coma

• Have poorly controlled hypertension

• Have any of the following cardiovascular conditions within 3 months prior to screening:

  • acute myocardial infarction
  • cerebrovascular accident (stroke)
  • unstable angina, or
  • hospitalization due to congestive heart failure

• Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure

• Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes

• Have ongoing or a history of bradyarrhythmias other than sinus bradycardia

• Have renal impairment

• Have a history of symptomatic gallbladder disease within the past 2 years

• Have signs and symptoms of any liver disease

• Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality

• Have a history of acute or chronic pancreatitis

• Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.